苦参素联合大剂量胸腺肽治疗拉米夫定停药后肝炎临床观察  

Clinical Observation of Curing Hepatitis of Stopping Lamivudine by Using Oxymatrine and High dose of Thymosin

作　　者：吴新员[1] 黎志良[1] 周伶俐[1] 黄佳[1] 

机构地区：[1]湖北省通城县人民医院,湖北通城437400

出　　处：《河北医学》2011年第2期155-158,共4页Hebei Medicine

摘　　要：目的:探讨苦参素联合大剂量胸腺肽治疗拉米夫定停药后肝炎临床疗效。方法:将60例拉米夫定停药后肝炎患者随机分为对照组与治疗组,对照组28例给予甘利欣、门冬氨酸钾镁等综合治疗;治疗组32例在对照组基础上给予胸腺肽和苦参素治疗。观察两组治疗前后肝功能变化、肝功能复常率、HBsAg、HBeAg和HBV-DNA阴转情况及临床疗效。结果:治疗后,治疗组的ALT、AST及TBIL值远低于对照组,两组比较差异均有统计学意义(P<0.05),且两组与治疗前比较,肝功能指标均有明显改善(P<0.05);治疗组ALT及TBIL复常率明显高于对照组(P<0.05);治疗组HBsAg、HBeAg及HBV-DNA阴转率高于对照组(P<0.05);治疗组的临床疗效优于对照组(P<0.05)。结论:苦参素联合大剂量胸腺肽治疗拉米夫定停药后肝炎临床疗效确切,值得推广应用。Objective： To investigate the clinical efficacy of hepatitis of stopping lamivudine by using oxymatrine combined with high dose of thymosin.Method： 60 patients with hepatitis after stopping lamivudine were randomLy divided into control group and treatment group,28 patients in control group were given glycyrrhizin,potassium magnesium and other comprehensive treatment;32 cases in the treatment group were given oxymatrine and high dose of thymosin.After that,observed the changes of liver function and liver function recovery rate,HBsAg,HBeAg and HBV-DNA negative conversion and clinical efficacy.Result： After treatment,,The value of ALT,AST and TBIL in the treatment group were much lower than the control group,there were significant differences between the two groups（P〈0.05）,and before the treatment,the liver function were significantly improved（P〈0.05）;The normalization rate of TBIL and ALT were significantly higher（P〈0.05） than the control group;The negative conversion rate of HBsAg,HBeAg and HBV-DNA in treatment group were higher than the control group;（P〈0.05）;The clinical efficacy in the treatment group was better than the control group（P〈0.05）.Conclusion： High dose of thymosin combied with oxymatrine cured hepatitis after stopping lamivudine therapy is effective,which should be widely applied.

关 键 词：苦参素 胸腺肽 拉米夫定 肝炎 

分 类 号：R512.62[医药卫生—内科学]